Unknown

Dataset Information

0

Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma.


ABSTRACT: Chimeric antigen receptor (CAR) T-cell therapy has changed the landscape of immunotherapy for B-cell malignancies, including mature B-cell lymphomas. Although two CD19 CAR T-cell products have been commercially approved to treat relapsed/refractory B-cell lymphomas, outcomes in these patients remain inferior to those of patients with B-cell leukemia, regardless of therapy. Recent clinical studies and preclinical reports suggest that certain characteristics, such as the suppressive lymphoma tumor microenvironment and inferior endogenous T-cell fitness, may contribute to discrepant responses in these patients. In addition, these studies revealed that limited CAR T-cell persistence and tumor antigen escape, which also impact B-cell acute lymphoblastic leukemia, may play a more prominent role in lymphoma. Multiple promising strategies to overcome these barriers have advanced to clinical trials. In this review, we assess CAR T-cell therapies for pediatric relapsed/refractory mature B-cell lymphomas, potential obstacles diminishing antitumor activity and limiting CAR T-cell persistence, and current strategies to overcome these obstacles.

SUBMITTER: Hsieh EM 

PROVIDER: S-EPMC7727550 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma.

Hsieh Emily M EM   Rouce Rayne H RH  

Hematology. American Society of Hematology. Education Program 20201201 1


Chimeric antigen receptor (CAR) T-cell therapy has changed the landscape of immunotherapy for B-cell malignancies, including mature B-cell lymphomas. Although two CD19 CAR T-cell products have been commercially approved to treat relapsed/refractory B-cell lymphomas, outcomes in these patients remain inferior to those of patients with B-cell leukemia, regardless of therapy. Recent clinical studies and preclinical reports suggest that certain characteristics, such as the suppressive lymphoma tumor  ...[more]

Similar Datasets

| S-EPMC5990429 | biostudies-literature
| S-EPMC8798430 | biostudies-literature
| S-EPMC7766167 | biostudies-literature
| S-EPMC9639856 | biostudies-literature
| S-EPMC8873350 | biostudies-literature
| S-EPMC7072387 | biostudies-literature
| S-EPMC10529970 | biostudies-literature
| S-EPMC7544150 | biostudies-literature
| S-EPMC5599075 | biostudies-literature
| S-EPMC8408091 | biostudies-literature